Skip to contentpdufa.bio
Home › Decisions › REGN 2026-11-18

REGN FDA decision: announced Nov 18, 2026

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET
✓ APPROVED

Livsayis (Cemdisiran (C5 RNAi)) was approved by the FDA for generalized myasthenia gravis (gMG) in adults who are anti-AChR antibody-positive; the approval was announced on November 18, 2026.

Verified against: FDA action day not found in a public FDA record · Announcement November 18, 2026 (Regeneron press release) · Goal month November 2026, no day stated (Regeneron 8-K).

This page was first committed to pdufa.bio's public repository on Nov 18, 2026, 10:14 PM ET (public commit b4707b1). Dates on this page are the FDA's and the sponsor's; this line is ours.

Run-up into the decision (T-120 → T+0)

announced 11/18/26$973.36$600.665/29/26announced 11/18/26$973.36$600.665/29/26
Daily close, T-120 (5/29/26) through T+0. Run-up high $973.36 on 11/3/26, low $600.66 on 6/1/26 (T-120 to T-1). Decision announced 11/18/26. Historical price action, not a forecast.

Key facts

FDA decision datenot found in a public FDA record
Announced2026-11-18
OutcomeApproved
Drug / candidateLivsayis (cemdisiran)
IndicationGeneralized myasthenia gravis in adults who are anti-AChR antibody-positive
CompanyRegeneron Pharmaceuticals
Market-cap tierLarge
120-day run-up (T-120→T-1)+54.1%
Decision-day move-1.3%
Move measured on2026-11-18 close (the announcement day), against the 2026-11-17 close
Cohort decision-day move (history)1.0% median (n=828)

Regeneron announced on November 18, 2026 that the FDA approved Livsayis (cemdisiran), given under the skin four times a year, for adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody-positive (Regeneron's announcement). The FDA's own record of the action day had not been posted when this page was published. Regeneron stated the target action date as November 2026 after using a Priority Review Voucher (Regeneron 8-K, July 30, 2026); because that is a month, not a day, no early or late margin is given. Per Regeneron, in the Phase 3 NIMBLE trial the MG-ADL score improved 4.5 points with Livsayis versus 2.2 with placebo at week 24 (p=0.0005), and 76.6% versus 44.1% of patients improved by at least 3 points. Livsayis carries a boxed warning for serious meningococcal infections and is available only through a REMS.

Run-up figures are the stock's own daily closing path over the 120 trading days before the decision, from our price history. Cohort move is the historical median absolute decision-day move for this market-cap tier. History, not a prediction.

Primary source: Regeneron press release, November 18, 2026

Questions

Was cemdisiran approved by the FDA?

Yes. Regeneron announced on November 18, 2026 that the FDA approved Livsayis (cemdisiran) for adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody-positive. The FDA's own record of the action day had not been posted when this page was published.

Which company is behind Livsayis (cemdisiran)?

Livsayis (cemdisiran) is a Regeneron Pharmaceuticals (REGN) program. The company announced the FDA decision on November 18, 2026; the company's own announcement is linked on this page.

How did REGN stock react to the FDA decision?

REGN moved -1.3%, measured as the 2026-11-18 close (the announcement day) against the 2026-11-17 close. It is one trading day's move, so it can include news other than the decision. Historical measurement, not a prediction, and not investment advice.

Was the Livsayis decision early?

pdufa.bio does not publish a margin for this decision. Regeneron stated the target action date as November 2026, a month rather than a day, after using a Priority Review Voucher, and the approval was announced on November 18, 2026, within that month.

What did the NIMBLE trial show?

Per Regeneron, at week 24 the MG-ADL score improved 4.5 points with Livsayis versus 2.2 with placebo, and 76.6% of patients versus 44.1% on placebo had at least a 3-point improvement. Livsayis is given under the skin four times a year and carries a boxed warning for serious meningococcal infections.